Gan & Lee Pharmaceuticals
Biosimilar developer, China. 3 development products across 3 molecules: insulin aspart, insulin glargine, insulin lispro.
First approval in the Atlas: Jan 2026, Ondibta, insulin glargine (EMA)
FDAproducts approved0
EMAproducts approved3
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Insulin aspart | Dazparda | · | Apr 2026 | · | · | · | · |
| Insulin glargine | Ondibta | · | Jan 2026 | · | · | · | · |
| Insulin lispro | Bysumlog | · | May 2026 | · | · | · | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- EMAJan 2026Ondibta, insulin glargine
- EMAApr 2026Dazparda, insulin aspart
- EMAMay 2026Bysumlog, insulin lispro
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.